MYOV News and Press, Myovant Sciences Ltd. From 02/07/19

BASEL, Switzerland , Feb. 7, 2019 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases, today announced corporate update...

CytomX Therapeutics (NASDAQ: CTMX ) initiated with Buy rating and $32 (68% upside) price target at H.C. Wainwright citing bullish prospects for Probody platform. More news on: CytomX Therapeutics, Rocket Pharmaceuticals, Inc., ObsEva, Healthcare stocks news, Stocks on the move, , Read ...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global...